Jia S, et al. - Given that, the BuMA biodegradable polymer (BP) sirolimus-eluting stent (SES; with faster drug elution and polymer absorption) was found non-inferior to the Excel SES in target lesion failure (TLF) in the previously published PANDA III study, researchers performed this current investigation to compare these two BP SESs in a subgroup of complex patients and lesions. For inclusion in PANDA III trial, patients were required to qualify one or more of the following criteria: Small vessel disease (reference vessel diameter ≤ 2.5 mm); long lesion (lesion length ≥ 20 mm); chronic total occlusion lesion; and diabetic patients. BuMA SES offered increased safety benefit, which was more prominently evident in complex patient and lesion population, as revealed in two-year subgroup analysis of the all-comer PANDA III trial.